IPO - Outlook Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465925052469

Filing Summary: Outlook Therapeutics, Inc. offers 9,285,714 shares of common stock and accompanying purchase warrants to purchase an aggregate of 18,571,428 shares of common stock at an exercise price of $1.40 per share. The securities are immediately separable and will be issued separately. The company’s common stock trades on the Nasdaq under the symbol 'OTLK.' The price per share is $1.40, and the offering is expected to raise approximately $13 million before underwriter discounts and commissions. The net proceeds will be used for working capital and general corporate purposes. The company has received marketing authorization in the EU and UK for its treatment of wet age-related macular degeneration (wet AMD) and is currently progressing through clinical development for approval in the U.S. after a previous BLA submission. They plan to launch in the U.S. if their product is approved and their ongoing trials are successful. The prospectus highlights investment risks and the company's history as a smaller reporting company, impacting certain disclosure obligations.

Form Type: 8-K

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465925052452

Filing Summary: On May 22, 2025, Outlook Therapeutics, Inc. entered into an Underwriting Agreement with BTIG, LLC for the issuance and sale of 9,285,714 shares of its common stock, along with accompanying warrants for the purchase of 18,571,428 shares of common stock. The combined offering price is set at $1.40 per share, including the accompanying warrants, with a gross proceeds estimate of approximately $13.0 million before expenses. The Offering is scheduled to close around May 27, 2025, pending customary closing conditions. Each warrant has an initial exercise price of $1.40 and is exercisable immediately, expiring five years post-issuance. Limitations on warrant exercises apply to prevent individual ownership exceeding specified thresholds. The Offering is being conducted under an effective registration statement on Form S-3. GMS Ventures and Investments has committed to purchase approximately $6.0 million worth of shares and warrants.

Form Type: 424B5

Filing Date: 2025-05-22

Corporate Action: Ipo

Type: New

Accession Number: 000110465925052010

Filing Summary: Outlook Therapeutics, Inc. is conducting an initial public offering involving shares of common stock and accompanying purchase warrants to purchase additional shares of common stock. The common stock is to be sold in combination with a purchase warrant to acquire two shares per each share sold. The initial exercise price and other specific financial details remain undisclosed. The securities are expected to be delivered to investors around a date in 2025, although the exact date is pending. The document highlights the company's recent milestones, including the recent marketing authorizations in the EU and UK for ONS-5010/LYTENAVA, which is approved for the treatment of wet age-related macular degeneration (AMD). The FDA has a BLA under review for the same product, and the company has resumed its application after addressing prior feedback. Additionally, the firm's securities are traded under the Nasdaq symbol 'OTLK'. The offering is subject to various risks, including the company's ability to continue as a going concern. Despite recent authorizations, the company expresses the need for substantial additional funding to support ongoing operations and product development beyond existing markets.